via fiercepharma.com
In a filing Thursday, it just said that the SEC has started a probe of its sales and marketing departments and that last month it received a subpoena tied to the Foreign Corrupt Practices Act (FCPA). Nothing more was disclosed and the company didn't want to comment, reports the Financial Times.
No comments:
Post a Comment